Compliance concerns hinder rollout of AI in drug manufacturing: Survey

Compliance concerns hinder rollout of AI in drug manufacturing: Survey

A recent survey by CRB found that compliance concerns are hindering the rollout of AI in drug manufacturing.

The survey, part of CRB's Horizons: Life Sciences report, suggests that AI is being used in biopharma for administrative tasks and drug discovery efforts, but not in regulated biopharma manufacturing.

More than 90% of drugmakers have yet to commit to scaling AI use in this area, indicating a significant gap in adoption.